#$%^&*AU2013254923A120131128.pdf#####ABSTRACT The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.1/20 LNA anti-miR 122a down-regulation of miR-122a, in Huh-7 cell line 1,0 N00 _A __ _ _ Mock SPC3370 SPC3372 SPC3375 SPC3349 SPC330 (mismatch control) LNA anti-miR ID Figure 1
